Health Claims

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.

Assertion

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

Assertion

Peptides marketed for fat loss often lack robust human evidence, relying instead on animal data or short-term biomarkers without long-term clinical validation.

Assertion

After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.

Descriptive

Even when accounting for factors like age, weight, and insulin levels, higher IGF-I still links to better muscle energy recovery in obese people with low growth hormone.

Correlational

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

Correlational

When IGF-I levels go up in obese people with low growth hormone, their muscle's ability to recover energy after exercise also improves, and this connection is statistically significant.

Correlational

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

Causal

The catalyst completely breaks down benzene gas into harmless CO2 and water, making it effective for air purification.

Descriptive

The electron transfer pathway keeps useful reactive particles active while reducing less useful ones, improving the catalyst's efficiency.

Mechanistic

Computer models show electrons move from zinc hydroxystannate to titanium dioxide at their interface following a specific pathway.

Mechanistic

Scientists observed that benzene breaks down into smaller molecules like phenolate, acetate, maleate, and methylene during the cleaning process using a special light-based technique.

Mechanistic

This new catalyst cleans benzene from air using UV light, processing 1.71 liters of air per minute, removing benzene at 21.9 micromoles per gram per hour, and using light efficiently with a quantum yield of 0.000608 molecules per photon per gram.

Quantitative

Tesamorelin only targets dangerous belly fat in HIV patients, leaving other fat stores like arms and legs unchanged.

Descriptive

Tesamorelin boosts a key growth hormone-related protein in HIV patients without affecting their blood sugar levels.

Causal

Doctors see noticeable improvements in the belly shape of HIV patients taking tesamorelin, while those on a dummy pill show no change.

Causal

HIV patients with belly fat buildup feel better about their appearance after taking tesamorelin, while those on a dummy pill don't notice a difference.

Causal

If HIV patients stop taking tesamorelin and switch to a dummy pill, their dangerous belly fat quickly returns to previous levels.

Causal

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

Causal

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

Causal

Cells with MOTS-c used less oxygen, but adding folic acid brought oxygen use back to normal.

Mechanistic

MOTS-c injections made mice burn more glucose instead of fat, as shown by higher CO2 output relative to oxygen use.

Quantitative

When mice fasted, MOTS-c levels dropped in muscles and blood but stayed the same in brain and heart.

Descriptive

Muscle cells engineered to produce MOTS-c used up glucose from their environment faster than normal cells.

Quantitative